LENZ Therapeutics
A late clinical-stage biopharmaceutical company developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia.
The California-based company's lead candidate is LNZ100, a preservative-free, single-use, once-daily eye drop containing aceclidine. In March 2024, LENZ completed the Phase III CLARITY trials of LNZ100, with an NDA submission being planned for mid-2024.
Latest LENZ Therapeutics News & Features
4 April 2024
1 December 2023
16 November 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze